Condition: Glaucoma · Primary Open Angle Glaucoma (POAG) · Neuroprotection · Sponsor: Institut Catala de Retina
This study aims to evaluate the effects of BrudyGlauco, a nutritional supplement containing DHA (docosahexaenoic acid) and citicoline, on visual function in people with glaucoma. Glaucoma is a progressive optic neuropathy that can lead to vision loss. Current treatments focus on lowering eye pressure, but there are other pathogenic factors and the use of additional therapies that could protect or regenerate the optic nerve would be beneficial. This is a randomized, double-blind, placebo-controlled, and multicenter clinical trial. Participants will be randomly assigned to receive either BrudyGlauco or a placebo for 12 months. The study will assess changes in visual field, safety, and treatment adherence. The trial is being conducted at the Institut Català de Retina (ICR) and Hospital de la Esperanza. Participants will undergo regular eye exams, visual field tests, and follow-ups to monitor potential improvements in visual function. The results of this study will help determine if BrudyGlauco can provide neuroprotective benefits for people with glaucoma and improve their quality of life.
This description comes directly from the study's public registry record.
Alfonso Antón Lopez Antón Lopez, Prof MD PhD · +34 93 4340553 · alfonso.anton@icrcat.com
Estela del Mar Sánchez Sotano, Biomedical science · 93 253 16 47 · estela.sanchez@icrcat.com
Always discuss trial participation with your own doctor first.
| Institut Català de Retina | Barcelona, Barcelona, Spain | Recruiting |
| Hospital del Mar | Centre Esperança | Barcelona, Barcelona, Spain | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07322965